Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1 medications are considered long-term, chronic-disease therapies for both diabetes and obesity
Their liposomal version showed encapsulation efficiencies of 86.38% to 87.3% across different formulations, meaning most of the glutathione stays protected
Our program brings together the benefits of cutting-edge medication with the vital support necessary for GLP-1 behavior changes to stick
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
